• Sleep-wake disorders

Sunosi Generic Name & Formulations

General Description

Solriamfetol 75mg+, 150mg; tabs; +scored.

Pharmacological Class


How Supplied

Tabs—30, 100

Generic Availability


Sunosi Indications


To improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Limitations of Use

Not for treating underlying airway obstruction in OSA. Ensure underlying airway obstruction is treated (eg, CPAP) for ≥1 month before initiation. Modalities to treat underlying airway obstruction should be continued during treatment with Sunosi. Sunosi is not a substitute for these modalities.

Sunosi Dosage and Administration


Take upon awakening; avoid within 9hrs of planned bedtime. Narcolepsy: initially 75mg once daily; usual range 75–150mg once daily. OSA: initially 37.5mg once daily; usual range 37.5–150mg once daily. For both: may double dose at intervals of ≥3 days; max 150mg once daily. Moderate renal impairment (eGFR 30–59mL/min/1.73m2): initially 37.5mg once daily; may increase to max 75mg once daily after ≥7 days. Severe renal impairment (eGFR 15–29mL/min/1.73m2): initially and at max 37.5mg once daily. ESRD (eGFR <15mL/min/1.73m2): not recommended.


Not established.

Sunosi Contraindications


During or within 14 days of MAOIs.

Sunosi Boxed Warnings

Not Applicable

Sunosi Warnings/Precautions


Assess BP and HR regularly prior to initiation and during therapy. Patients with higher risk of cardiovascular events (esp. known cardio- or cerebrovascular disease, pre-existing hypertension, advanced age). Consider discontinuing if BP or HR increases unmanageable. History of psychosis or bipolar disorders. Monitor for emergence or exacerbation of psychiatric symptoms; consider dose reduction or discontinuation if develop. Abuse potential. Drug or alcohol abuse. Reevaluate periodically. Moderate or severe renal impairment: adjust dose. Elderly: use lower doses; monitor. Pregnancy. Nursing mothers: monitor infants.

Sunosi Pharmacokinetics


Renal. Half-life: 7.1 hours.

Sunosi Interactions


See Contraindications. May increase risk of hypertensive reaction with concomitant MAOIs. Caution with concomitant dopaminergic drugs or other drugs that increase BP and/or HR.

Sunosi Adverse Reactions

Adverse Reactions

Headache, nausea, decreased appetite, insomnia, anxiety, dry mouth, constipation.

Sunosi Clinical Trials

See Literature

Sunosi Note


Enroll pregnant patients in the Sunosi Pregnancy registry by calling (877) 283-6220.

Sunosi Patient Counseling

See Literature